C3 and myeloid sarcoma: In a mouse model of MS, where synapse loss in grey matter regions precedes axonal degeneration (independent of demyelination) (87), genetic deletion of C3 can ameliorate both microglial activation as well as neural dysfunction (88) suggesting that targeting the complement system may have therapeutic potential for treating chronic neuroinflammatory illnesses before symptoms arise.